TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04470076
Drug: Adjuvant treatment:afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The CR, PR and SD patients who have been treated surgically will take afatinib at a dosage of 30mg per day for 2 year.
Study: NCT00697138
Drug: d-Amphetamine; Atomoxetine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
Study: NCT04161248
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP
Study: NCT04161248
Drug: Rituximab Injection
Normalized name: rituximab Injection
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 - Day 1, cycle 1.
Study: NCT04161248
Drug: Rituximab SC
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1400 mg fixed dose - Day 1, cycle 2 and 3
Study: NCT04161248
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 - Day 1 to day 8
Study: NCT04161248
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg daily - Day 1 to day 4
Study: NCT04161248
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2 - Day 1
Study: NCT04161248
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP
Study: NCT04161248
Drug: Tafasitamab
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15)
Study: NCT02291458
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 gram L-arginine / day for 6 weeks
Study: NCT00199303
Drug: pre-operatively followed by 30 mg three times per day after surgery
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00194532
Drug: Cefpodoxime
Normalized name: Cefpodoxime
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime 100mg twice a day(BID)for 3 days
Study: NCT00194532
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin 250mg twice a day (BID)for 3 days
Study: NCT01139138
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6mg/kg IV every 14 days
Study: NCT01305993
Drug: SB injection
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
Study: NCT02840591
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02840591
Drug: Citicoline
Normalized name: Citicoline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01445509
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
Study: NCT05326269
Drug: Terbutaline
Normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT03136848
Drug: Normothermic ex-vivo kidney perfusion Solution -Toronto
Normalized name: Allogeneic, ex-vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells - cultured fraction (CF)
DrugBank: Omidubicel (DB17132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney.
Study: NCT01445509
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
Study: NCT01139138
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 200mg/m2 IV every 14 days
Study: NCT01139138
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus daily po (dosage varies with cohort)
Study: NCT00752206
Drug: Saracatinib
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Agent
Study: NCT04326283
Drug: Trametinib (0.5 mg)
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mg/day
Study: NCT04326283
Drug: Trametinib (1 mg)
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg/day
Study: NCT04326283
Drug: Riluzole (100 mg)
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/day (50 mg twice)
Study: NCT04520646
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: empagliflozin of 10mg/day is added on the basis of primary care
Study: NCT03542175
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
Study: NCT01046838
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg three times daily for 9 weeks
Study: NCT00004554
Drug: naltrexone (Revia)
Normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/day
Study: NCT00004554
Drug: sertraline (Zoloft)
Normalized name: sertraline Oral Solution [Zoloft]
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg/day
Study: NCT01015118
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (standard chemo-therapy)
Study: NCT01015118
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (standard chemo-therapy)
Study: NCT02586649
Drug: Tiotropium Bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
Study: NCT02896413
Drug: Dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
Study: NCT02152930
Drug: Omega-3 fatty acids
Normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
Study: NCT01615913
Drug: 3 mg terbinafine and 2 mg ketoconazole containing patch
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
Study: NCT01615913
Drug: 6 mg terbinafine and 2 mg ketoconazole containing patch
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
Study: NCT01615913
Drug: 8 mg terbinafine and 2 mg ketoconazole containing patch
Normalized name: terbinafine 14.8 MG/ML
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
Study: NCT04374942
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.
Study: NCT00006119
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00084136
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg taken orally daily
Study: NCT00084136
Drug: Didanosine (enteric-coated)
Normalized name: didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg taken orally daily
Study: NCT00084136
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg taken orally daily
Study: NCT00084136
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg taken orally daily
Study: NCT00084136
Drug: Emtricitabine/Tenofovir disoproxil fumarate
Normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/300 mg taken orally once daily
Study: NCT00084136
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/300 mg taken orally twice daily
Study: NCT03374852
Drug: CPI-613
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
Study: NCT03794336
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study: NCT03794336
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study: NCT03794336
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study: NCT03794336
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study: NCT03404752
Drug: Peg-Filgrastim
Normalized name: peg-filgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00373113
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 37.5 mg daily, continuous dosing
Study: NCT01742117
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 75 mg tablet per day by mouth for one year
Study: NCT01742117
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 90 mg tablet twice per day by mouth for one year
Study: NCT00674713
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00975689
Drug: N-Acetyl Cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
Study: NCT04335136
Drug: RhACE2 APN01
Normalized name: rhACE2
DrugBank: Alunacedase alfa (DB15736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with APN01 intravenously twice daily (BID).
Study: NCT02715440
Drug: Immediate intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual withdrawal of benzodiazepines or related drugs
Study: NCT00587496
Drug: valacyclovir hydrochloride
Normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg capsule, one per day for 30 days
Study: NCT00587496
Drug: valacyclovir plus aspirin
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
Study: NCT01642472
Drug: Ulipristal Acetate - open label
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
Study: NCT00905437
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg BD for 14 days
Study: NCT01367626
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg tablet
Study: NCT01329562
Drug: Treximet
Normalized name: Treximet
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
Study: NCT00002738
Drug: trimetrexate glucuronate
Normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03005015
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03362411
Drug: BMS-986205
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single 100 mg dose on Day 1 and Day 15
Study: NCT00742235
Drug: ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol 50,000 IU given every other day for 5 total doses
Study: NCT00433004
Drug: Plan B (Levonorgestrel)
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
Study: NCT03534180
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03534180
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00220636
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
Study: NCT01169818
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target
Study: NCT00171756
Drug: valsartan/atenolol
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01119209
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved by the Danish Medicines Agency
Study: NCT00352664
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
Study: NCT02127788
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous
Study: NCT01119209
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved by the Danish Medicines Agency
Study: NCT05532306
Drug: Ribavirin 400 mg film coated tablet (1*400mg)
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: an immediate release film-coated tablet containing 400 mg Ribavirin
Study: NCT00539942
Drug: Arixtra (fondaparinux sodium)
Normalized name: fondaparinux sodium Prefilled Syringe [Arixtra]
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
Study: NCT02259777
Drug: Telmisartan/Amlodipine
Normalized name: telmisartan/amlodipine 40 mg-5 mg ORAL TABLET
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose combination tablet
Study: NCT01866605
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.3 mg/kg
Study: NCT01305577
Drug: Deoxycholic acid injection
Normalized name: deoxycholic acid Injection
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04232761
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administration as determined by treating physician
Study: NCT02649751
Drug: Roscovitine
Normalized name: R-roscovitine
DrugBank: O6-(R)-ROSCOVITINE, R-2-(6-BENZYLOXY-9-ISOPROPYL-9H-PURIN-2-YLAMINO)-BUTAN-1-OL (DB04770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
Study: NCT02136069
Drug: Etrolizumab
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.
Study: NCT02136069
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
Study: NCT01655004
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
Study: NCT03139591
Drug: lidocaine inhalation; intravenous dexamethasone
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
Study: NCT00256256
Drug: glucagon-like-peptide-1
Normalized name: Glucagon-like-peptide-1 (7-36) amide
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 1.2pmol/kg/min for 6 hours
Study: NCT00241839
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
Study: NCT00241839
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Study: NCT02231931
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose, fasted
Study: NCT02231931
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose, fasted